Published in Chest on June 01, 2013
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2014) 1.73
Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest (2013) 1.02
Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol (2015) 0.92
The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. Biomed Res Int (2015) 0.83
Diagnosis and management of interstitial lung disease. Transl Respir Med (2014) 0.83
Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int (2014) 0.82
Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther (2014) 0.81
Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2/ angiotensin-(1-7) axis in rats. Int J Med Sci (2014) 0.81
Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers. Pulm Circ (2015) 0.80
New approaches to modulating idiopathic pulmonary fibrosis. Curr Allergy Asthma Rep (2013) 0.79
Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med (2015) 0.79
The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int (2013) 0.78
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. Biomed Res Int (2015) 0.78
The St. George's Respiratory Questionnaire as a prognostic factor in IPF. Respir Res (2017) 0.75
Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation. Pulm Circ (2016) 0.75
Pulmonary hypertension's variegated landscape: a snapshot. Pulm Circ (2017) 0.75
Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis. Pulm Circ (2017) 0.75
Pulmonary hypertension associated with lung diseases and hypoxemia. Heart Fail Rev (2016) 0.75
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet (2002) 4.63
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes (2007) 3.66
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med (2002) 3.32
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest (2006) 2.73
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest (2005) 2.60
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med (2004) 1.84
Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest (2007) 1.73
Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest (2007) 1.66
Pulmonary diseases and the heart. Circulation (2007) 1.52
Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration (1983) 1.34
Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension. Respirology (2011) 1.27
The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest (2005) 1.11
Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis. Respiration (2012) 0.83
Pulmonary hypertension in interstitial lung disease. Int J Clin Pract Suppl (2008) 0.79
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med (2015) 8.70
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2006) 4.95
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 4.81
Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One (2011) 4.65
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Mechanisms of pulmonary fibrosis. Annu Rev Med (2004) 4.37
Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med (2008) 4.33
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol. Anesth Analg (2014) 4.19
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med (2009) 4.05
CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol (2005) 4.02
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care (2007) 3.53
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J (2002) 2.95
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med (2007) 2.80
Spirometry utilization for COPD: how do we measure up? Chest (2007) 2.77
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol (2006) 2.68
Predicting death in patients with acute type a aortic dissection. Circulation (2002) 2.68
Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med (2008) 2.65
Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med (2012) 2.65
Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation (2006) 2.60
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2009) 2.58
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med (2003) 2.35
Angiotensin-converting enzyme inhibitor therapy at the time of coronary artery bypass surgery: when a friend turns mean-spirited. J Am Coll Cardiol (2009) 2.32
A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med (2006) 2.28
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 2.20
Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2007) 2.19
Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med (2008) 2.15
Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax (2012) 2.15
Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol (2003) 2.14
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.10
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA (2007) 2.10
Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J (2005) 2.09
The solitary pulmonary nodule. Chest (2003) 2.09
Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs (2004) 2.05
Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect Immun (2004) 2.04
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med (2007) 2.04
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax (2013) 1.99
Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.98
Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis (2002) 1.98
A prospective multicenter study of competency metrics and educational interventions in the learning of bronchoscopy among new pulmonary fellows. Chest (2009) 1.97
Significance of the microbiome in obstructive lung disease. Thorax (2012) 1.97
Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med (2007) 1.94
Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med (2007) 1.94